Guidelines of the French Society of Otorhinolaryngology (SFORL) (short version). Specific treatment of epistaxis in Rendu-Osler-Weber disease

Eur Ann Otorhinolaryngol Head Neck Dis. 2017 Feb;134(1):37-41. doi: 10.1016/j.anorl.2016.09.010. Epub 2016 Dec 14.

Abstract

Objectives: The authors present the guidelines of the French Oto-Rhino-Laryngology - Head and Neck Surgery Society (Société Française d'Oto-Rhino-Laryngologie et de Chirurgie de la Face et du Cou: SFORL) concerning specific treatment of epistaxis in Rendu-Osler-Weber disease.

Methods: A multidisciplinary work-group was entrusted with a review of the scientific literature on the above topic. Guidelines were drawn up, based on the articles retrieved and the group members' individual experience. They were then read over by an editorial group independent of the work group. The final version was established in a coordination meeting. The guidelines were graded as A, B, C or expert opinion, by decreasing level of evidence.

Results: Rendu-Osler-Weber disease is diagnosed from the presence of at least three of Curaçao's four criteria. In acute epistaxis, bidigital compression is recommended. Embolization is reserved for resistant epistaxis. Non-resorbable nasal packing and cauterization are contraindicated. Patient education is essential. Telangiectasia of the nasal mucosa can be treated by various local means. In the event of insufficient control, systemic administration of tranexamic acid is recommended.

Keywords: Anemia; Epistaxis; Reference center; Rendu-Osler-Weber disease.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Antifibrinolytic Agents / therapeutic use
  • Catheter Ablation
  • Epistaxis / etiology*
  • Epistaxis / therapy*
  • Hemostatic Techniques
  • Hemostatics / therapeutic use
  • Humans
  • Laser Therapy
  • Patient Education as Topic
  • Telangiectasia, Hereditary Hemorrhagic / complications
  • Telangiectasia, Hereditary Hemorrhagic / diagnosis*
  • Tranexamic Acid / therapeutic use

Substances

  • Antifibrinolytic Agents
  • Hemostatics
  • Tranexamic Acid